For regulatory approval, biosimilar drugs must not have any clinically-meaningful differences compared to the approved medications they are modeled after. To evaluate the safety, pureness, and potency of biosimilars, drug developers use advanced instruments to quickly perform multiplex analyses and assess characteristics including target binding, performance, and toxicity.
Download this infographic from Sartorius to learn more about services to the obstacles experienced when defining biosimilar drugs.
